Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares [Yahoo! Finance]
TG Therapeutics (NASDAQ:TGTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $49.00 to $46.00. They now have an "overweight" rating on the stock.
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
TG Therapeutics: The 'Exit Velocity' You Can't Ignore (Rating Upgrade) [Seeking Alpha]
TG Therapeutics (NASDAQ:TGTX) was given a new $39.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a "neutral" rating on the stock.